- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA clears mammography workstation
The regulatory path is clear for Hologic to begin marketing its SecurViewDX breast imaging workstation. The FDA earlier this month cleared the dedicated workstation for display and interpretation of screening and diagnostic digital mammograms, as well as
The regulatory path is clear for Hologic to begin marketing its SecurViewDX breast imaging workstation. The FDA earlier this month cleared the dedicated workstation for display and interpretation of screening and diagnostic digital mammograms, as well as other images such as MRI, CT, PET, and ultrasound. The workstation can also support digital CAD programs. It will complement Hologic's Lorad Selenia full-field digital mammography system, but its use will not be restricted to this system. The SecurViewDX is FDA cleared as an adjunct to any FDA-approved FFDM system.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
